BNGO - Bionano More Likely To Transform Into A Clinical Lab Than Succeed In Marketing Saphyr
- Cold response to Saphyr from the medical community and the acquisition of BioDiscovery and Lineagen position BNGO into becoming a clinical lab instead of a Life Science equipment manufacturer.
- The acquisition of Lineagen and BioDiscovery diversifies BNGO's portfolio, brings it closer to the mainstream genome analysis, and provides it with a safety net in case its OGM pitch fails.
- The 20% quarter-over-quarter sequential growth is disappointing, considering the low comparable revenue base of $4 million and considering it includes non-organic revenue from the acquisition.
For further details see:
Bionano More Likely To Transform Into A Clinical Lab Than Succeed In Marketing Saphyr